Reuters logo
BRIEF-GSK gets accelerated FDA approval for combination use of Mekinist and Tafinlar
January 9, 2014 / 1:50 AM / 4 years ago

BRIEF-GSK gets accelerated FDA approval for combination use of Mekinist and Tafinlar

Jan 9 (Reuters) - GlaxoSmithKline Plc : * Says gains accelerated FDA approval for combination use of

Mekinist(trametinib) and Tafinlar (dabrafenib) * Mekinist, Tafinlar approved for patients with unresectable melanoma or

metastatic melanoma with BRAF V600E or V600K mutations *

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below